Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute

Published 20/05/2024, 19:18
© Reuters Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
PFE
-
AZN
-
PBYI
-

Benzinga - by Vandana Singh, Benzinga Editor.

A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights.

The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx.

Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs.

Puma Biotechnology Inc (NASDAQ:PBYI), which sells Nerlynx under a license from Pfizer, was initially part of the lawsuit but is no longer a plaintiff.

AstraZeneca expressed disappointment with the verdict. Citing the company’s spokesperson, Reuters noted that it is “confident in our IP position in relation to Tagrisso” and plans to “vigorously defend” its rights.

Despite the setback, AstraZeneca maintains that its drug does not infringe on the patents and argues that patents themselves are invalid.

Read Next: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac.

Pfizer initiated the lawsuit against AstraZeneca in 2021, arguing that Tagrisso’s use of kinase inhibitors to treat cancer mirrored the method used by Nerlynx. In 2023, AstraZeneca reported Tagrisso sales of $5.8 billion.

The case is not yet fully resolved. U.S. District Judge Matthew Kennelly is scheduled to hold a separate bench trial in June to address some of AstraZeneca’s remaining defenses.

This forthcoming trial could alter the outcome of the jury’s decision, adding another layer of uncertainty to the ongoing legal battle.

On Monday, AstraZeneca also announced its plans to build a $1.5 billion manufacturing facility in Singapore to produce antibody-drug conjugates, a category of cancer-killing drugs.

The Singapore Economic Development Board will support the facility, which will be AstraZeneca’s first end-to-end ADC production site.

The company said the facility’s construction will begin by the end of 2024 and should be operational by 2029. It added that it will have zero carbon emissions from its first day of operations.

Price Action: AZN shares are up 0.16% at $77.03 at last check Monday.

Photo via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.